



## **Zaprinast**

Catalog #: 27218

Size: 10 mg

CAS Registry #: 37762-06-4


**Purity**: ≥98%

Chemical Formula: C<sub>13</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub>

Molecular Weight: 271.3

Lot #: 120608

Structure:



**Description:** Zaprinast is a cGMP-specific PDE inhibitor which moderately inhibits PDE5 and PDE6. It weakly inhibits PDE9, PDE10 and PDE11. Sildenafil (Viagra<sup>™</sup>) was developed from Zaprinast, which enhances the vasodilatory effects of nitric oxide in a range of vascular tissues by prolonging the cGMP-mediated activation of cGMP-dependent protein kinase. Also, GPR35 is activated by Zaprinast.

Appearance: A crystalline solid

**Solubility:** Soluble in DMSO and DMF, purged with an inert gas. Solubility in DMSO and DMF is ~10 mg/ml. For maximum solubility, dissolve in DMF and then dilute with the aqueous buffer of choice. Do not store aqueous solutions for more than one day.

**Biological Activity:** Zaprinast inhibits PDE5 and PDE6 with IC<sub>50</sub> values of 0.5-0.76  $\mu$ M and 0.15  $\mu$ M, respectively.

**Storage/Stability:** Store at or below -20°C for up to two years.

**Quality Control:** The purity was determined by HPLC analysis.

## References:

1. Nakamizo, T., et al., J. Neurosci. Res. 2003;**71**:485-495.

2. Gibson, A., et al., Eur. J. Pharmacol. 2001;411:1-10.

3. Taniguchi, Y., et al., FEBS Lett. 2006;**580**:5003-5008.